Latest News and Press Releases

GUANGZHOU, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, received prominent...

The XS LLM integrates five intelligent agents into a closed-loop system covering the full chronic disease management cycle.

Fangzhou Wins Tencent Health ‘AI-Powered Future Award’ as MaaS Platform Drives AI Chronic Care.

Fangzhou expects full-year revenue for 2025 to reach between RMB 3.5 billion and RMB 3.55 billion, representing year-on-year growth of approximately 30%

Fangzhou plans to allocate approximately 90% of the net proceeds to accelerate development of the Company's AI-driven chronic disease management platform.

Fangzhou Inc. and Tencent Healthcare jointly launched a comprehensive “AI+Chronic Disease Management” solution.

Fangzhou was recognized with the “Social Responsibility Golden Bull Award”.

Fangzhou was presented with a Generative AI Service Filing Certificate at the first Guangdong Provincial LLM Filing Conference.

Fangzhou and Fosun Pharma plan to build partnership in AI-powered chronic disease management, initially focused on psoriasis and other autoimmune condition

Fangzhou plans to expand its "AI + Weight Management" ecosystem through broader applications, data-driven innovation, and cross-industry collaboration.